Hormone replacement therapy (HRT) has become one of the most talked-about topics in women's health — and for good reason. For millions of women experiencing menopause symptoms, HRT can be transformative. But starting HRT without baseline lab testing is like adjusting a prescription without knowing your starting dose. Lab work before, during, and after starting HRT is essential for safe and effective treatment.
Whether you're exploring HRT for the first time or already on therapy and wondering if your dose is right, this guide covers exactly which lab tests matter and why.
Why Lab Testing Matters for HRT
Menopause hormone therapy isn't one-size-fits-all. The type, dose, and route of hormones that work for one woman may be completely wrong for another. According to the 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS), individualized therapy guided by symptoms and clinical assessment — including lab monitoring — can produce good outcomes.
Lab testing serves three critical purposes:
1. Establishing a baseline before starting therapy 2. Optimizing dosing once therapy begins 3. Monitoring safety markers over time
Essential Lab Tests Before Starting HRT
1. Estradiol (E2)
Estradiol is the primary estrogen your ovaries produce and the form most commonly replaced in HRT. Baseline levels may point to menopausal status and can provide a reference point for dosing.
- Premenopausal range: 30-400 pg/mL (varies by cycle day)
- Postmenopausal (no HRT): Can be below 20 pg/mL
- Optimal on HRT: Practitioners may target 50-150 pg/mL depending on symptoms and route of administration
2. FSH (Follicle-Stimulating Hormone)
FSH can rise as ovarian function declines. A high FSH may point to menopause and can provide context for estrogen levels.
- Premenopausal: 3-10 mIU/mL (follicular phase)
- Postmenopausal: Can be above 30 mIU/mL
- On HRT: FSH can decrease but may not need to reach premenopausal levels
3. Progesterone
If you have a uterus, you need progesterone alongside estrogen to protect the endometrial lining. Baseline testing may show you're not already supplementing or producing significant progesterone.
4. Total and Free Testosterone
Testosterone can decline by approximately 50% between your 20s and menopause (Davis & Wahlin-Jacobsen, 2015). Many menopausal symptoms — low libido, fatigue, brain fog, muscle loss — may be partially driven by testosterone decline.
- Premenopausal total testosterone: 15-70 ng/dL
- Postmenopausal: Can be below 20 ng/dL
- SHBG should be tested alongside, as it can determine how much testosterone is biologically active
5. Complete Thyroid Panel
Thyroid symptoms overlap significantly with menopause symptoms — and thyroid dysfunction can become more common after 40. Ruling out or identifying thyroid issues before starting HRT can prevent misattribution of symptoms.
- TSH — screening marker
- Free T4 and Free T3 — actual hormone levels
- TPO antibodies — Hashimoto's screening (affects up to 10% of postmenopausal women)
6. Metabolic Panel
Menopause can increase cardiovascular and metabolic risk. These baseline markers are essential:
- Fasting insulin — may be an early marker of metabolic dysfunction
- Fasting glucose and HbA1c — diabetes screening
- Lipid panel — total cholesterol, LDL, HDL, triglycerides
- hsCRP — inflammatory marker that may be linked to cardiovascular risk
Estrogen can be cardioprotective, and part of HRT's benefit may be metabolic — but you need a baseline to track improvement (Manson et al., 2013).
7. Vitamin D and Ferritin
Both can be deficient in menopausal women and can affect bone health, energy, mood, and immune function. Optimizing these alongside HRT can improve outcomes.
- Vitamin D goal may be: 40-60 ng/mL
- Ferritin goal may be: 50-100 ng/mL
Monitoring Labs While on HRT
Once you've started HRT, follow-up testing can help ensure your doses are correct and your body is responding safely.
6-8 Weeks After Starting or Adjusting Dose
This is the sweet spot for retesting. Hormone levels may have stabilized by this point.
Recheck:
- Estradiol — is it in the target range for your route?
- Progesterone (if supplementing) — adequate for endometrial protection?
- Testosterone (if supplementing) — in female physiological range?
- SHBG — oral estrogen can raise SHBG, which can bind testosterone and reduce its effectiveness
Route-Specific Considerations
The route of administration can affect which labs matter most:
Oral estrogen:
- Can raise SHBG significantly (first-pass liver effect)
- Can increase clotting factors — check SHBG as a proxy for hepatic effect
- May raise triglycerides
Transdermal estrogen (patches, gels, creams):
- Bypasses the liver, may have minimal effect on SHBG and clotting factors
- May be preferred for women with cardiovascular risk factors or migraines (Scarabin, 2018)
- Estradiol levels can be tested reliably via blood draw
Pellets/injections:
- Can produce supraphysiological peaks — timing of blood draw relative to insertion/injection matters
- Test at trough (just before next dose) for the most accurate picture
Every 6-12 Months Ongoing
Once stable, annual monitoring should include:
- Estradiol and progesterone — can help check ongoing adequacy
- Testosterone and SHBG — especially if libido or energy symptoms persist
- Thyroid panel — thyroid needs can shift with HRT
- Metabolic markers — fasting insulin, glucose, HbA1c, lipids
- Vitamin D — ongoing optimization
- CBC — basic blood health monitoring
Red Flags That May Suggest Your HRT Needs Adjustment
Your labs and symptoms together can tell the story. Watch for these signals:
- Persistent hot flashes or night sweats — estradiol may be too low
- Breast tenderness or bloating — estradiol may be too high, or progesterone type/dose may need adjustment
- Mood symptoms (anxiety, irritability) — check progesterone levels and type; consider testosterone
- Low libido despite adequate estrogen — testosterone may be too low or SHBG too high
- Fatigue and brain fog — recheck thyroid, testosterone, and metabolic markers
- Breakthrough bleeding — evaluate endometrial thickness; adjust progesterone
What Optimal Levels May Look Like on HRT
While ranges vary by practitioner and individual, here are general targets many integrative and menopause-specialist providers use:
- Estradiol: 50-150 pg/mL (symptom-dependent)
- Progesterone: Variable by type; oral micronized progesterone levels are difficult to measure accurately via blood
- Total testosterone: 30-60 ng/dL (if supplementing)
- Free testosterone: 1-5 pg/mL
- SHBG: 30-80 nmol/L (watch for elevations above 100 on oral estrogen)
- TSH: 0.5-2.5 mIU/L (may be optimal, not just "normal")
- Vitamin D: 40-60 ng/mL
The Bottom Line
HRT can be life-changing — but it may work best when guided by data. Baseline lab testing before starting, follow-up testing at 6-8 weeks, and ongoing annual monitoring can help ensure you're on the right type, dose, and route for your body. Don't settle for a prescription without a lab panel to guide it.
Take the Quiz
Not sure which hormones to test or whether HRT may be right for you? Take our free Biomarker Quiz to get personalized lab test recommendations based on your symptoms. It takes about 3 minutes — and it's the smartest first step toward informed hormone therapy.
References
- The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. PMID 35797481
- Davis, S. R., & Wahlin-Jacobsen, S. (2015). Testosterone in women — the clinical significance. The Lancet Diabetes & Endocrinology, 3(12), 980-992. PMID 26358173
- Manson, J. E., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 310(13), 1353-1368. PMID 24084921
- Scarabin, P. Y. (2018). Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis. Climacteric, 21(4), 341-345. PMID 29570359
- Slopien, R., et al. (2018). Menopause and diabetes: EMAS clinical guide. Maturitas, 117, 6-10. PMID 30314563
- Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. PMID 26444994
